Metergoline as a lactation inhibitor.
For the prevention of lactation we administered metergoline, 12 to 16 mg per day for five to ten days, to six groups of 100 patients each with excellent or good results in 95% to 99% of the cases. In addition, metergoline was given to 100 patients in order to suppress previously established lactation, with excellent or good results in 100% of the cases. The decrease of prolactin during the first 21 days of metergoline administration was compared with that in a group given bromoergocriptine (5 mg per day) and with that in a breast-binding control group. Metergoline is effective and does not have secondary effects in the inhibition and suppression of lactation due to its antiserotonin and dopaminergic effects.
D001971:Bromocriptine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D008711:Metergoline / Q000008:administration & dosage / Q000494:pharmacology*; D049590:Postpartum Period; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D013997:Time Factors
D004873:Ergolines; D008711:Metergoline; D001971:Bromocriptine; D011388:Prolactin